MS patients on anti-CD20 therapy have robust T cell responses to SARS-CoV-2 vaccination

· by · in Biotechnology industry, iPS Cells, Personalized Therapies, Regenerative Medicine. ·


Study: Discordant humoral and T cell immune responses to SARS-CoV-2 vaccination in people with multiple sclerosis on anti-CD20 therapy. Image Credit: Kateryna Kon/ Shutterstock
https://www.news-medical.net/news/20210827/MS-patients-on-anti-CD20-therapy-have-robust-T-cell-responses-to-SARS-CoV-2-vaccination.aspx

Leave a Reply

Fill in your details below or click an icon to log in:

Gravatar
WordPress.com Logo

You are commenting using your WordPress.com account. ( Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. ( Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. ( Log Out /  Change )

Cancel

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.